Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN)

Are you curious about what drives a biopharmaceutical company focused on developing treatments for life-threatening diseases? Have you ever wondered how a company's mission, vision, and core values translate into tangible results? For Day One Biopharmaceuticals (DAWN), these aren't just words on a wall. In 2024, Day One Biopharmaceuticals reported $57.2 million in OJEMDA net product revenues, demonstrating significant commercial momentum. But what exactly is the mission that fuels this growth, and what vision guides their path forward?

Dive in to explore the mission, vision, and core values that shape Day One Biopharmaceuticals, and discover how these elements contribute to their goal of bringing life-changing medicines to patients, starting from Day One.

Day One Biopharmaceuticals, Inc. (DAWN) An Overview of

Day One Biopharmaceuticals is focused on developing and commercializing therapies for childhood cancers. The company aims to address unmet needs in pediatric oncology by bringing innovative treatments to young patients. Day One's key product is Tovorafenib, an oral brain-penetrant RAF inhibitor, which has shown promise in clinical trials for pediatric low-grade glioma (pLGG). As of April 2025, Day One continues to advance its clinical programs and expand its reach in the pediatric oncology space. The company's mission is centered around improving outcomes for children and young adults with cancer. To learn more, check out this investor profile: Exploring Day One Biopharmaceuticals, Inc. (DAWN) Investor Profile: Who’s Buying and Why?

Day One Biopharmaceuticals has demonstrated robust financial performance, particularly highlighted in their recent financial reports. In 2024, the company reported significant revenue growth driven primarily by the commercialization of OJEMDA (tovorafenib). For the full year of 2024, OJEMDA net revenue was $47.8 million, with $17.2 million in the fourth quarter. This substantial revenue underscores the increasing market adoption of their key product. Day One's strategic focus on key markets and effective commercial strategies have contributed to this impressive growth. Additionally, the company's investments in research and development continue to support the expansion of their product pipeline. The company's cash, cash equivalents, and marketable securities totaled $357.9 million as of December 31, 2024.

Day One Biopharmaceuticals is emerging as a leader in the pediatric oncology sector. The company's dedication to addressing unmet needs in childhood cancer, coupled with its strong financial performance and strategic initiatives, positions it as a key player in the industry. Day One is not just developing drugs; it is aiming to transform the landscape of pediatric cancer treatment. Discover more about what makes Day One a successful and impactful company in the biopharmaceutical industry:

• Innovative Therapies: Focus on developing novel treatments for pediatric cancers.
• Strategic Growth: Expansion in key markets and effective commercial strategies.
• Financial Strength: Robust revenue growth and strong financial management.

Day One Biopharmaceuticals, Inc. (DAWN) Mission Statement

Day One Biopharmaceuticals is dedicated to changing what's possible for people, families and healthcare providers impacted by childhood cancer. They rally the community to drive awareness and develop new, promising treatments for unmet needs. They strive to create a brighter future where every child has the opportunity to live a long and healthy life. Day One Biopharmaceuticals' mission is deeply rooted in addressing the unique challenges of pediatric oncology and reflects a comprehensive approach to improving patient outcomes and supporting their families.

The core components of Day One Biopharmaceuticals' mission statement are:

• Focus on Childhood Cancer: Day One is dedicated to developing and commercializing therapies to address unmet needs in pediatric oncology.
• Community and Collaboration: They emphasize rallying the community to drive awareness and support.
• Innovation and Impact: The mission includes developing new, promising treatments for unmet needs, aiming for a brighter future where every child has the opportunity to live a long and healthy life.

Let's break down these components to understand the full scope of their mission.

Focus on Childhood Cancer

Day One Biopharmaceuticals directs its efforts and resources specifically to combating childhood cancers. This targeted focus allows them to concentrate expertise and resources on the distinct challenges presented by pediatric oncology. According to the American Cancer Society, in 2024, an estimated 10,470 children in the United States aged 0-14 years will be diagnosed with cancer. This specificity ensures that their research and development efforts are tailored to meet the unique needs of young patients, who often respond differently to treatments than adults.

Community and Collaboration

Day One Biopharmaceuticals recognizes that fighting childhood cancer requires a united front. By rallying the community, including families, healthcare providers, researchers, and advocacy groups, they aim to create a strong support network and drive awareness. This collaborative approach is essential for fostering innovation and ensuring that new treatments reach the children who need them most. Collaboration is also important in clinical trials. In 2023, it was noted that more than 15,000 children and adolescents participate in clinical trials for cancer treatments, highlighting the collaborative effort to find better solutions.

Innovation and Impact

At the heart of Day One Biopharmaceuticals' mission is a commitment to innovation. They are dedicated to developing new and promising treatments that can transform the lives of children with cancer. This involves not only scientific research but also a focus on improving the overall quality of life for patients and their families. Their ultimate goal is to create a brighter future where every child has the opportunity to live a long and healthy life, reflecting a deep sense of hope and determination. According to a 2024 report, investments in pediatric cancer research have led to a 30% increase in survival rates over the past two decades, underscoring the impact of focused innovation.

To gain more insights into the financial strategies and overall health of the company, check out this comprehensive analysis: Breaking Down Day One Biopharmaceuticals, Inc. (DAWN) Financial Health: Key Insights for Investors

Day One Biopharmaceuticals, Inc. (DAWN) Vision Statement of

To provide context, Day One Biopharmaceuticals, Inc. is dedicated to developing and commercializing therapies for childhood cancers. Understanding their mission, vision, and core values provides insight into their strategic goals and operational philosophy. As of April 2025, this chapter examines these guiding principles, incorporating the most recent data and relevant information.

Day One Biopharmaceuticals' mission is laser-focused on changing the landscape of pediatric cancer treatment. Their mission is reflected in their commitment to finding and developing new treatments that address the unmet needs of children with cancer. As of their 2024 fiscal year, this mission is reflected in their research and development efforts, with a significant portion of their resources allocated to pediatric oncology programs. You can explore more about Day One Biopharmaceuticals, Inc. (DAWN) Investor Profile here: Exploring Day One Biopharmaceuticals, Inc. (DAWN) Investor Profile: Who’s Buying and Why?

Their mission is supported by several key activities:

• Drug Development: Focusing on innovative therapies that target the unique biology of childhood cancers.
• Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of their drug candidates.
• Partnerships: Collaborating with leading research institutions and other pharmaceutical companies to accelerate the development of new treatments.

The vision of Day One Biopharmaceuticals is to become a leader in pediatric oncology by creating a world where every child with cancer has a chance for a healthy future. This vision drives their strategic decisions and long-term goals. The company's focus extends beyond just developing drugs; they envision a comprehensive approach to cancer care that includes early diagnosis, personalized treatment, and supportive care for patients and their families.

Key elements of their vision include:

• Innovation: Pioneering new scientific approaches to target childhood cancers more effectively.
• Accessibility: Ensuring that their treatments are accessible to all children, regardless of their socioeconomic status or geographic location.
• Collaboration: Working closely with healthcare providers, patient advocacy groups, and other stakeholders to improve the overall cancer care ecosystem.

Day One Biopharmaceuticals' core values define the company's culture and guide its employees' behavior. These values include:

• Patient-Centricity: Putting the needs of patients and their families first in every decision they make.
• Integrity: Upholding the highest ethical standards in their research, development, and business practices.
• Innovation: Embracing creativity and a willingness to challenge the status quo in the pursuit of new therapies.
• Collaboration: Fostering a culture of teamwork and partnership to achieve common goals.
• Excellence: Striving for the highest levels of quality and performance in all aspects of their work.

These core values influence how Day One Biopharmaceuticals operates daily, from research and development to patient interactions. For instance, their commitment to patient-centricity is evident in their patient support programs, which provide resources and assistance to families affected by childhood cancer.

Day One Biopharmaceuticals, Inc. (DAWN) Core Values of

Day One Biopharmaceuticals, Inc. (DAWN) operates with a clear mission and vision, underpinned by a set of core values that guide its actions and decisions. These values reflect the company's commitment to patients, innovation, and collaboration. The core values serve as the foundation for its culture, influencing how employees interact with each other, partners, and the broader community. Here's an overview of these guiding principles:

Patients First

At Day One Biopharmaceuticals, putting patients first is more than just a slogan; it's a deeply ingrained commitment that shapes every aspect of the organization's work. This core value means prioritizing the needs and well-being of patients above all else, ensuring that decisions are made with their best interests in mind. Day One is dedicated to developing and delivering innovative therapies that can improve the lives of individuals battling cancer, especially children. This involves not only creating new treatments but also working to make them accessible to those who need them most.

Examples of how Day One Biopharmaceuticals demonstrates its commitment to putting patients first include:

• Clinical Trials: Day One Biopharmaceuticals focuses on conducting clinical trials that are designed to be patient-centric, incorporating feedback and insights from patients and their families to optimize the trial experience.
• Patient Advocacy: The company actively engages with patient advocacy groups to understand the challenges faced by patients and to support initiatives that improve their care and quality of life.
• Compassionate Use Programs: Day One Biopharmaceuticals provides access to its investigational therapies for patients with serious or life-threatening conditions when no other treatment options are available.

Innovation

Innovation is a driving force at Day One Biopharmaceuticals. The company is dedicated to pushing the boundaries of science and technology to develop groundbreaking therapies for cancer. This commitment to innovation is evident in its research and development efforts, as well as its willingness to explore new approaches and collaborations.

Examples of how Day One Biopharmaceuticals fosters innovation:

• Research and Development: Day One Biopharmaceuticals invests heavily in research and development, seeking out novel targets and mechanisms of action to create innovative cancer treatments. For example, the company’s 2024 R&D expenses were $134.1 million, compared to $98.4 million in 2023.
• Strategic Partnerships: The company collaborates with leading academic institutions, research organizations, and other biotechnology companies to accelerate the development of new therapies.
• Technology Platforms: Day One Biopharmaceuticals utilizes cutting-edge technology platforms to identify and develop promising drug candidates, including genomics, proteomics, and bioinformatics.

Collaboration

Collaboration is essential to Day One Biopharmaceuticals' success. The company recognizes that solving the complex challenges of cancer requires working together with a diverse range of stakeholders, including patients, physicians, researchers, and other industry partners. By fostering a culture of collaboration, Day One Biopharmaceuticals aims to leverage the collective expertise and resources of its network to advance the development of new therapies.

Examples of how Day One Biopharmaceuticals promotes collaboration:

• Cross-Functional Teams: Day One Biopharmaceuticals establishes cross-functional teams that bring together experts from different areas of the company to work together on projects and initiatives.
• External Partnerships: The company actively seeks out partnerships with external organizations to access new technologies, expertise, and resources.
• Open Communication: Day One Biopharmaceuticals encourages open communication and knowledge sharing among its employees and partners to foster a collaborative environment.

Day One Biopharmaceuticals' commitment to its core values is evident in its actions and achievements. By putting patients first, fostering innovation, and promoting collaboration, the company is making a meaningful difference in the lives of people affected by cancer. The company's financial performance reflects its dedication to these values. As of the 2024 fiscal year, Day One reported total assets of $501.7 million and total liabilities of $75.5 million, demonstrating a strong financial foundation to support its ongoing research and development efforts.